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Abstract To investigate whether magnetization transfer
imaging (MTI) is a useful detector of diffuse brain
abnormalities in ‘premanifest’ carriers of the Huntington’s
disease (HD) gene mutation. Furthermore we examined the
relations between MTI, clinical measures and CAG repeat
length. Sixteen premanifest carriers of the HD gene without
motor manifestation and 14 non-carriers underwent a
clinical evaluation and a MRI scan. MTI analysis of whole
brain, grey matter and white matter was performed pro-
ducing magnetization transfer ratio (MTR) histograms. A
lower peak height of the grey matter MTR histogram in
carriers was signiﬁcantly associated with more UHDRS
motor abnormalities. Furthermore, a lower peak height of
the whole brain, grey and white matter was strongly
associated with a longer CAG repeat length. MTI measures
themselves did not differ signiﬁcantly between carriers and
non-carriers. In premanifest HD mutation carriers, a lower
MTR peak height, reﬂecting worse histological brain
composition, was related to subtle motor abnormalities and
higher CAG repeat length. Although we could not detect
altered MTI characteristics in carriers of the HD gene
mutation without clinical manifestations, we did provide
evidence that the MTR peak height might reﬂect genetic
and subclinical disease burden and may be of value in
monitoring further disease progression and provide insight
in clinical heterogeneity.
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Introduction
Huntington’s disease (HD) is a hereditary neurodegenera-
tive disorder resulting in a progressive loss of motor and
cognitive functioning and changes in mood and social
behavior. The genetic defect leads to cell death especially
in the basal ganglia. Recent studies demonstrated that the
amount of white matter and cortical grey matter is found to
be reduced as well, even early in the disease [5, 21, 23].
Improving the knowledge of brain changes in ‘premanifest’
carriers (further labeled as carriers) of the HD gene
mutation (i.e. without overt clinical signs) is essential in the
search for sensitive instruments suitable to monitoring HD
onset and progression for future therapeutic trials with
neuroprotective agents.
Volumetric MRI studies in carriers demonstrated smal-
ler basal ganglia volumes even years before the onset of
motor disturbances [4, 7, 17, 21]. Recent voxel based
morphometry (VBM), diffusion tensor imaging (DTI) or
positron emission tomography (PET) studies demonstrated
abnormalities in white matter and cortical grey matter as
well [8, 23, 24, 30]. Other quantitative MRI techniques,
such as magnetization transfer imaging (MTI) may further
improve our understanding of how diffuse brain changes in
HD develop and how these are related to the genotype and
the heterogeneous phenotype of the disease. In MTI the
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water is represented by the magnetization transfer ratio
(MTR), which can be demonstrated quantitatively in the
MTR histogram. A low peak height of the MTR histogram
indicates reduced capacity of the macromolecules in brain
tissue to exchange magnetization with the surrounding
water molecules, reﬂecting structural brain damage [14].
MTI has the advantage of being non-invasive and easy to
administer, whilst having been proved to be sensitive for
the ﬁrst microstructural brain changes in different neuro-
degenerative disorders, like Alzheimer’s disease (AD) and
Parkinson’s disease (PD), even before volumetric altera-
tions [2, 16, 29, 33, 36, 37]. In mild cognitive impairment
(MCI), which has become increasingly recognized as a
transitional phase between normal old age and AD,
abnormal MTR values of the brain parenchyma could be
demonstrated without evidence of atrophy [33].
Although MTI was initially developed to investigate
white matter changes in multiple sclerosis (MS), it was
demonstrated to be sensitive for changes in tissue structure
of the grey matter as well [13, 31, 37]. This, and the sen-
sitivity for histopathological changes preceding atrophy,
makes MTI an attractive tool in studying the earliest dif-
fuse brain changes related to HD in both grey matter and
white matter. To date, only one study investigated MTI
parameters in predominantly symptomatic HD gene carri-
ers [20]. No signiﬁcant differences in mean MTR values
between HD patients and controls were found. However,
this study did not address the peak height of the MTR
histograms, which has proven to be the most sensitive and
distinctive MTI parameter for detecting brain damage in
various neurodegenerative diseases [6, 22, 32, 37]. Lower
peak heights of the histogram could be demonstrated in
AD, MCI and MS, while mean MTR values were still
within the normal range [31, 33, 36].
Therefore, in this explorative study, we investigated
whether MTI based magnetization transfer ratios and his-
togram peak heights could reveal diffuse brain abnormal-
ities in carriers in comparison with non-carriers by
studying the total of brain parenchyma, the grey matter and
the white matter. It is hypothesized that MTI may provide
additional information on diffuse brain pathology and its
relation with the genotype and the phenotype in the pre-
manifest phase of HD.
Patients and methods
Seventeen carriers and 15 non-carriers were invited to
participate in this study. All participants were recruited
from the Leiden University Medical Center (LUMC) out-
patient Neurological department. Participants had under-
gone gene testing according to international guidelines at an
earlier time [1]. The median CAG repeat length in carriers
was 42 (range 40–49) and in non-carriers 19 (range 16–24).
The estimated probability of symptom onset within 5 years
was determined [19]. Carriers were considered ‘premani-
fest’ in the absence of ‘deﬁnite’ motor signs on the uniﬁed
Huntington’s disease rating scale (UHDRS), as assessed
during their last visit to our outpatient department. Reas-
sessment of motor functioning during study enrolment by a
neurologist blind to genetic status, resulted in the exclusion
of one carrier who was rated as deﬁnite HD. One non-carrier
who showed evidence of overt cerebral damage on MRI was
also excluded from analysis. Ultimately analyses were
performed on 16 carriers and 14 non-carriers.
The study had been approved by the local Medical
Ethical Committee. Written informed consent was obtained
from all subjects.
Procedure
All participants were evaluated with the UHDRS and MRI
of the brain [17, 18]. There were no more than 4 months
between clinical assessment and MRI-scan (mean 30 days,
SD 44 days).
From the motor part of the UHDRS the total motor score
(TMS) was used (max 0–124), with higher scores repre-
senting more motor abnormalities. The cognitive and
behavioral sections of the UHDRS were administered by a
psychologist. The total behavioral score was obtained by
adding the products of frequency and severity for each
item.
Image acquisition
All imaging was performed on a whole body MR system
operating at ﬁeld strength of 3.0 T (Philips Medical Sys-
tems, Best, The Netherlands). MRI consisted of a 3D-T1-
weighted and magnetization transfer imaging (MTI) scan.
Acquisition parameters were as follows: 3D-T1-weighted:
TR = 9.8 ms; TE = 4.6 ms; ﬂip angle = 8; section
thickness = 1.2 mm; number of sections = 120; no sec-
tion gap; whole brain coverage; FOV = 224 mm;
matrix = 192, reconstruction matrix = 256; 3D-gradient
echo MTI: TR = 100 ms; TE = 3.7 ms; ﬂip angle = 8;
section thickness = 7.2 mm; number of sections = 20; no
section gap; whole brain coverage; FOV = 224 mm;
matrix = 224, reconstruction matrix = 256. These scan
parameters were chosen to minimize T1 and T2 weighting,
resulting in a proton-density contrast in the absence of MT
saturation pulses. Two consecutive sets of images were
acquired; the ﬁrst was performed in combination with the
MT saturation pulse, and the second without. In the second
scan a sinc-shaped saturation pulse 1,100 Hz below fre-
quency of water was added.
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Images were transferred to an ofﬂine LINUX workstation.
All MTR processing steps were performed using the
FMRIB’s software library (FSL) [25]. The MTR sequence
was split into an m0 dataset, which represents the signal
intensity of voxels without saturation and an m1 dataset,
which represents the intensity of voxels with saturation. An
MTR map was obtained by calculating the MTR value for
each voxel using the formula; MTR = {(m0 – m1)/
m0} 9 100% [11]. To obtain segmented grey and white
matter the T1 weighted scans were segmented using the
segmentation tool in FSL, FAST [38]. All segmentations
were eroded one voxel in plane to minimize partial volume
effects on the MTI parameters. A transformation matrix was
usedtomaskthe MTRmap withthe segmentedwhole brain,
grey and white matter volume from the T1 weighted scan
segmentation. From the resulting MTR maps of the whole
brain, grey and white matter, histograms were created and
ﬁnally normalized forthe sizeof the region of interest.From
these histograms the peak height was derived. Whole brain,
grey and white matter volume was measured, using an
automated method, the cross-sectional version of the
Structural Image Evaluation of Normalized Atrophy (SIE-
NAx) [27]. Furthermore we measured relative brain atrophy
with SIENAx by accurately deﬁning brain size with respect
to skull size, normalized to a standard template, resulting in
normalized brain volumes. This also reduces within group
variations, making cross-group comparisons more sensitive
[26]. Manual segmentation of basal ganglia volumes in
these groups were described elsewhere [17].
Statistical analysis
SPSS for Windows (release 16.0.) was used for data
analysis. Group differences were analyzed with parametric
or non-parametric tests when appropriate. To assess dif-
ferences in age, education, UHDRS scores, brain volumes
and MTI parameters we used independent t tests. Pearson
correlation analysis (r) was used to investigate associations
of MTI measures with UHDRS scores and CAG repeat
length. The level of statistical signiﬁcance was set at
p B 0.01. Values of 0.01\p B 0.05 were considered as a
trend towards signiﬁcance.
Results
Clinical characteristics
There were no signiﬁcant differences between groups for
sex, age, years of education and UHDRS motor, cognitive
and behavioral functioning (Table 1).
MRI parameters
There were no signiﬁcant differences between groups for
whole brain, grey and white matter brain volumes and MTI
parameters (Table 2). An association between smaller brain
volumeandhigherage,wasfoundonlyinnon-carriers.Since
thestatisticalassumption‘homogeneityofregressionslopes’
was violated, covarying for age was not feasible. Further-
more as groups did not differ signiﬁcantly in age we decided
not to correct for this variable. We also investigated brain
volumes normalized for head size and found a tendency
towards smaller whole brain volume (p = 0.05), especially
whitematter(p = 0.03)incarrierscomparedtonon-carriers.
The results on the basal ganglia volumes in the studied
groups have been reported in an earlier study and showed
smaller caudate, putamen and globus pallidus volumes in
carriers [17].
Relations between UHDRS and MTI parameters
In gene carriers we found that a higher score on the
UHDRS motor scale, reﬂecting more motor abnormalities,
Table 1 Clinical characteristics
Carriers
(n = 16)
Non-carriers
(n = 14)
Male/female
a 6/10 6/8
Age (years) 41.9 (10.0) 47.2 (9.2)
Education (years) 12.9 (2.7) 12.6 (2.8)
CAG repeat length
b 42 (40–49) 19 (16–24)
Probability of onset within
5 years (%)
b,e
17 (0–73)
UHDRS
Total motor score
c,d 3.5 (0–10) 2.4 (0–6)
Verbal ﬂuency 38.5 (13.6) 39.0 (10.4)
SDMT 52.2 (11.8) 60.6 (11.7)
Stroop color 72.3 (13.0) 80.9 (16.2)
Stroop word 96.6 (10.6) 100.1 (19.6)
Stroop interference 42.3 (7.7) 45.6 (6.8)
Total behavioral score
d 12.4 (11.4) 15.8 (17.6)
Values in the table are means (SD)
No signiﬁcant differences were found between carriers and non-car-
riers, except for CAG repeat length (p = 0.00)
UHDRS uniﬁed Huntington’s disease rating scale, SDMT symbol digit
modalities test
Independent t test analysis
a Pearson’s v
2 test
b Median (range)
c Mean (range)
d Higher scores correspond with more abnormalities
e A greater probability of onset within 5 years corresponds with
being closer to estimated onset of disease
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123was signiﬁcantly associated with a lower peak height of the
grey matter MTR histogram (r =- 0.70, p = 0.003)
(Fig. 1) and marginally with a lower peak height of the
whole brain MTR histogram (r =- 0.57, p = 0.02).
Associations remained after controlling for basal ganglia
volume. From the UHDRS cognitive and behavioral
assessment in carriers, a signiﬁcant association was found
between lower white matter mean MTR and better scores
on the Stroop interference task (r =- 0.63, p = 0.009) and
marginally between lower whole brain peak height and
worse scores on the Stroop color naming task (r = 0.56,
p = 0.02). In non-carriers no signiﬁcant associations with
MTI parameters were found.
Relations between CAG and MTI parameters
A higher CAG repeat length in carriers was strongly related
to lower peak heights of the whole brain, grey and white
matter (r =- 0.87, p = 0.00; r =- 0.86, p = 0.00; r =
-0.68, p = 0.004) (see Fig. 2 for an example). A trend
association was found between higher CAG repeat length
and lower grey matter mean MTR (r =- 0.55, p = 0.03).
Furthermore, a greater probability of developing symptoms
within 5 years was marginally related to smaller grey
matter peak height (r =- 0.58, p = 0.02).
Discussion
Regional brain changes, speciﬁcally in the striatum, have
been demonstrated many years prior to the onset of clinical
signs in HD [3, 17, 21]. The onset and progression of early
diffuse brain changes in HD are imperfectly known. To the
best of our knowledge, this is the ﬁrst time that extensive
MTI analysis has been applied to study grey and white
matter in premanifest HD mutation carriers. In carriers
lower MTR peak height was speciﬁcally related to
decreased motor functioning and higher CAG repeat
Table 2 Volumes and MTI parameters of whole brain, grey matter
and white matter
Carriers
(n = 16)
Non-carriers
(n = 14)
P value
Whole brain
Volume (cc) 1150.1 (86.2) 1205.2 (108.8) 0.13
NBV 1492.8 (57.2) 1536.6 (59.5) 0.05*
MTRm 39.8 (0.6) 39.8 (0.9) 0.94
NPH 88.8 (8.3) 90.2 (5.2) 0.59
Grey matter
Volume (cc) 654.0 (51.0) 678.7 (70.2) 0.28
NBV 849.6 (50.0) 865.8 (62.3) 0.43
MTRm 37.6 (0.6) 37.7 (0.9) 0.59
NPH 87.7 (9.4) 90.1 (5.4) 0.40
White matter
Volume (cc) 496.1 (47.6) 526.5 (53.0) 0.11
NBV 643.2 (34.3) 670.9 (29.6) 0.03*
MTRm 43.4 (0.5) 43.3 (1.1) 0.72
NPH 147.6 (15.2) 155.3 (16.7) 0.20
Values in the table are means (SD)
The peak height was normalized for brain size of the region of interest
(number of voxels on the peak divided by the total number of seg-
mented voxels)
NBV normalized brain volume (normalized for skull size). MTRm
mean MTR, NPH normalized peak height
Independent t tests were used for statistical analysis
*p\0.05
Fig. 1 Signiﬁcant association in carriers between higher score on the
UHDRS motor scale and lower normalized peak height of the grey
matter
Fig. 2 Signiﬁcant association in carriers between higher CAG repeat
length and lower normalized peak height of the whole brain
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123length. Although we could not demonstrate MTR differ-
ences between carriers and non-carriers, the strong asso-
ciations with HD characteristics in carriers indicate that
MTR values might reﬂect disease burden.
In line with one previous study, predominantly including
symptomatic carriers, mean MTR values did not differ
between carriers and non-carriers [20]. We also studied the
more sensitive peak height of the MTR histogram and
could not demonstrate any brain abnormalities in carriers
with that parameter either. However, when volumes of the
whole brain, grey matter and white matter were normalized
for skull size, hereby measuring atrophy state, carriers had
a smaller volume of the whole brain parenchyma and
especially the white matter, indicating the presence of
global brain changes in carriers [26]. This is in accordance
with previous studies demonstrating early grey and white
matter tissue loss in premanifest HD [21, 23].
Our data show that in these areas of reduced grey and
white matter tissue MTR values were not abnormal, indi-
cating that the integrity of the tissue was not signiﬁcantly
altered on a group level. It might be that the speciﬁc HD
pathologic process does not result in altered tissue integ-
rity, conﬁrmed by the study of Mascalchi et al. [20] who
could not demonstrate MTI abnormalities in basal ganglia
of HD patients, despite smaller basal ganglia volumes
compared to controls. In other neurological diseases a
reduction in MTR has been especially associated to myelin
loss, axonal loss, gliosis and inﬂammation [9, 13, 33].
Since there is no unequivocal substrate underlying MTR,
the technique may be less sensitive for detecting other
microscopic changes, such as those in HD. Nevertheless,
the remarkably strong association between lower MTR
peak height and a higher CAG repeat length, indicates that
the integrity of the tissue reﬂects underlying genetic dis-
ease burden. Furthermore, clinical relevance of the MTR
was also demonstrated; lower whole brain and grey matter
peak height in carriers, reﬂecting less cerebral homogene-
ity, was found to be strongly related to more motor
abnormalities. Motor functioning has been linked to striatal
changes in previous premanifest studies [3, 7, 17]. Since
associations remained after controlling for basal ganglia
volumes, the ﬁndings might indicate the involvement of
more diffuse grey matter changes in altered motor
functioning.
It can be argued that with advancing motor abnormali-
ties and pathological burden the MTR peak heights con-
tinue to decrease and will signiﬁcantly differ from controls.
This is strengthened by the ﬁnding that MTR peak heights
tend to be somewhat lower in carriers in this study. Fur-
thermore, lower grey matter peak heights were associated
with a greater probability of developing symptoms within
5 years.
Various studies in other diseases, like Alzheimer’s dis-
ease and multiple sclerosis, related MTI measurements to
cognitive functioning, however results are inconsistent
[10, 31, 33, 35]. Surprisingly, we showed in carriers that a
lower mean value of white matter MTR, indicating worse
histological brain composition, was associated with better
performance on the Stroop interference task. Since mini-
mum variation isfoundinmeanMTR valuesinbothcarriers
and non-carriers this result has to be interpreted with cau-
tion. Furthermore MTR peak heights proved a better
reﬂection of abnormal brain structure in other MTI studies
of neurodegenerative diseases [6, 22, 32, 37]. Van der Flier
etal.[34]demonstrated astrongassociationbetweendiffuse
brain damage as measured with global MTR peak heights
and neuropsychological test results in mild cognitive
impairment and AD. We did show that lower whole brain
peak height was related to worse scores on the Stroop color
naming task. Snowden et al. [28] emphasized that relatively
automatic speed based tasks, such as this Stroop condition,
are most sensitive for HD related cognitive changes.
Strengths of the current study include the automated
segmentation methods for MRI data. Furthermore, we
associated MTI values with the full spectrum of HD
characteristics. Potential limitations include the small
sample size, which might have contributed to the absence
of a statistical difference in MTI characteristics between
carriers and non-carriers. Also the rather thick section
thickness of the MTI sequence might have contributed to
less sensitivity. Furthermore, carriers seemed quite far
from onset based on probability of onset estimations and on
the relatively low motor scores compared to other studies
in premanifest HD [12, 15]. A follow up of the current
cohort and a larger sample, including manifest HD carriers
as well, should shed more light on diffuse MTR abnor-
malities and motor and cognitive correlates in HD.
In conclusion, although we could not detect altered MTI
characteristics in carriers of the HD gene mutation without
clinical manifestations, we did provide evidence that the
MTR peak height might reﬂect genetic and subclinical
disease burden. Whether MTI parameters are sensitive for
HD related brain changes and associations with the phe-
notype in more advanced stages of disease remains to be
investigated.
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